About Ancora Pharmaceuticals
Ancora Pharmaceuticals is a company based in Milton Keynes (United Kingdom) founded in 2002 was acquired by Corden Pharma in October 2013. Ancora Pharmaceuticals has raised $800 thousand across 3 funding rounds from investors including HHS and Corden Pharma. Ancora Pharmaceuticals operates in a competitive market with competitors including Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
- Headquarter Milton Keynes, United Kingdom
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Ancora Pharmaceuticals Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$800 K (USD)
in 3 rounds
-
Latest Funding Round
$800 K (USD), Seed
Nov 24, 2009
-
Investors
HHS
& 1 more
-
Employee Count
Not available
-
Acquired by
Corden Pharma
(Oct 31, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ancora Pharmaceuticals
Ancora Pharmaceuticals has successfully raised a total of $800K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $800 thousand completed in November 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ancora Pharmaceuticals
Ancora Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Corden Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
CDMO offering its services for small molecules, peptides, lipids and carbohydrates
|
Locked | Locked | Locked |
Investor details for Ancora Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ancora Pharmaceuticals
Investment portfolio details for Ancora Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ancora Pharmaceuticals
Detailed financials for Ancora Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ancora Pharmaceuticals Comparisons
Peer comparison for Ancora Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ancora Pharmaceuticals
Ancora Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Provider of human monoclonal antibodies against infectious diseases
|
|
| Locked | Locked | Locked |
Antibiotics, antifungals, and oncology drugs are developed for disease treatment.
|
Detailed competitors of Ancora Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ancora Pharmaceuticals
Complete news archive for Ancora Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ancora Pharmaceuticals
Ancora Pharmaceuticals was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Ancora Pharmaceuticals is headquartered in Milton Keynes, United Kingdom.
Ancora Pharmaceuticals is a funded company, having raised a total of $800K across 3 funding rounds to date.
Ancora Pharmaceuticals was founded in 2002 and is located in Milton Keynes, United Kingdom. Focus is placed on the biotechnology sector, where vaccines targeting hospital-acquired infections such as those from Staphylococcus, Enterococcus, Candida, and Moraxella are developed. Lead candidates remain in preclinical development. Efforts also extend to vaccines addressing community-acquired infections and potential bioterrorism threats.
Ancora Pharmaceuticals's top competitors include Imvax, Aridis Pharma and Insmed.
Ancora Pharmaceuticals has 2 investors. Key investors include HHS, and Corden Pharma.